Bridgeway Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Bridgeway Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.54M	Buy	723,477 +550,177	+317%	+$1.31M	0.03%	597
2025 Q4	$421K	Buy	173,300 +75,000	+76%	+$266K	0.01%	857
2025 Q3	$373K	Hold	98,300	–	–	0.01%	865
2025 Q2	$244K	Buy	98,300 +25,200	+34%	+$48.6K	0.01%	920
2025 Q1	$113K	Sell	73,100 -71,500	-49%	-$150K	﹤0.01%	1015
2024 Q4	$309K	Sell	144,600 -4,600	-3%	-$13.2K	0.01%	916
2024 Q3	$649K	Sell	149,200 -23,800	-14%	-$130K	0.01%	800
2024 Q2	$806K	Hold	173,000	–	–	0.02%	745
2024 Q1	$877K	Sell	173,000 -19,000	-10%	-$76.6K	0.02%	776
2023 Q4	$540K	Buy	192,000 +65,500	+52%	+$154K	0.01%	921
2023 Q3	$363K	Buy	126,500 +51,500	+69%	+$190K	0.01%	969
2023 Q2	$379K	Hold	75,000	–	–	0.01%	981
2023 Q1	$142K	Sell	75,000 -50,000	-40%	-$115K	﹤0.01%	1169
2022 Q4	$225K	Hold	125,000	–	–	0.01%	1062
2022 Q3	$211K	Buy	125,000 +59,800	+92%	+$184K	0.01%	1130
2022 Q2	$160K	Sell	65,200 -12,000	-16%	-$27.9K	﹤0.01%	1137
2022 Q1	$214K	Buy	+77,200	New	+$282K	﹤0.01%	1160

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Bridgeway Capital Management's BDTX Position: Q1 2026 in Review

Bridgeway Capital Management increased its Black Diamond Therapeutics (BDTX) stake by 317% in Q1 2026, buying an estimated $1.31M and bringing the position to 723,477 shares worth $1.54M. The position accounts for 0.03% of the portfolio, ranked #597.

Bridgeway Capital Management first reported a position in BDTX in Q1 2022 and has held it in 17 quarters since. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

Bridgeway Capital Management held 723,477 shares of Black Diamond Therapeutics worth $1.54M as of Q1 2026.
Bridgeway Capital Management bought 550,177 Black Diamond Therapeutics shares in Q1 2026, an estimated $1.31M.
Black Diamond Therapeutics made up 0.03% of Bridgeway Capital Management's portfolio in Q1 2026, its #597 holding.
Bridgeway Capital Management first reported a position in Black Diamond Therapeutics in Q1 2022 and has held it in 17 quarters since.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.